ArticleAAPS PharmSciTech2026
Design, Optimization and Pharmacokinetic Profiling of BCS Class II Drug Loaded Oral Self Nanoemulsifying System.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The orally administered self nano emulsifying drug delivery system (SNEDDS), an uniform blend with nano scaled globules, is composed of oil, surfactant and co-surfactant. The aim of the investigation was to develop and optimize Nicardipine loaded liquid SNEDDS via Box Behnken design and characterised based on physicochemical features, DSC and stability profile. Further to achieve sustain drug release, the optimized SNEDDS was compressed as self nano emulsifying tablet (SNET). Furthermore, the in vivo and pharmacokinetic study of the drug loaded SNET (NT) were performed. The NOF indicated droplet size (75.62 nm ± 2.01), self emulsification time (37 s ± 1.01), and 87.6% ± 0.08drug release (at 1 h). The bias was found to be within the range of -0.72 to + 1.19 for stable, almost spherical, amorphous formulation. The sustained release (following Higuchi kinetics) of drug from NT was observed. The mean systolic blood pressure of NT treated rats were found to be significantly reduced (*p < 0.01) to normal range up to 48 h and the plasma NIC concentrations were found to be maintained up to 36 h with enhanced bioavailability in comparison to pure drug suspension. The enhanced NIC exposure of NT (AUC
Indexed as
Identifiers
42091771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.